An observational study in Iron Deficiency Anemia, Obesity and Sleeve Gastrectomy, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Cairo University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Anemia, Iron-Deficiency by Cairo University — 4 open to participants now, 4 under way, none of them phase 3. Anemia, Iron-Deficiency · Cairo University.
Among the 11 studies in Anemia, Iron-Deficiency by Cairo University, this one is one of 4 that started in 2026, is one of 3 observational ones, and was the 7th registered.
602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.
Browse Anemia, Iron-Deficiency studies →4 of the 11 studies in Anemia, Iron-Deficiency by Cairo University are open now, in 2 countries. Recruiting first, the newest first:
Cairo University · Sites in Saudi Arabia
Ages 14–14 · Women only · Healthy volunteers
Cairo University · Sites in Egypt
Ages 20–30 · Women only
Cairo University
Ages 19–25
By country, each count listing its studies:
Of the 53 Anemia, Iron-Deficiency studies recruiting now, 19 (36%) set no upper age limit and 30 (57%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 66 is below the median of 200 across 118 observational studies indexed under Anemia, Iron-Deficiency.
Median enrollment 75 across the 8 interventional studies, 100 across the 3 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
2 of the studies in Anemia, Iron-Deficiency by Cairo University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07397572Cairo UniversityIron Supplementation and Anemia After Sleeve Gastrectomy | 2026-11 |
| NCT07633262Cairo UniversityFACE-APPS-Based Approach for Improving Iron Deficiency Anaemia Indicators Among Female Adolescents at Marginalized Communities | 2026-11-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Anemia, Iron-Deficiency by Cairo University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn if taking extra iron pills after weight loss surgery helps prevent low iron and anemia compared to just taking a standard multivitamin. The main question it aims to answer is:
Does a specific iron supplementation plan lower the number of patients who develop iron deficiency anemia in the 6 months after sleeve gastrectomy surgery?
Researchers will compare two groups of patients from different hospital units to see if the extra iron works:
Patients from one unit who take a prophylactic iron supplement (Ferrodep, 60 mg per day) in addition to their standard multivitamin.
Patients from another unit who take only a standard multivitamin (Centrum Silver).
Participants in this study will:
Background and Rationale Iron deficiency anemia (IDA) is a prevalent and clinically significant long-term complication following Laparoscopic Sleeve Gastrectomy (LSG), the most commonly performed bariatric procedure worldwide. Despite universal multivitamin supplementation, the incidence of IDA rises steadily post-operatively, impacting patient quality of life, cognitive function, and healthcare utilization. A critical evidence gap exists regarding the efficacy of routine prophylactic oral iron supplementation compared to a strategy of standard multivitamin use with iron monitoring. Current guidelines lack consensus due to insufficient comparative long-term data. This study aims to provide high-level evidence to inform postoperative protocols by directly comparing these two distinct management strategies.
Study Design and Setting This is a prospective, observational, comparative cohort study conducted within the bariatric surgery units of Kasr Al-Ainy Hospital, Cairo University. The study leverages existing, routine clinical practices at two participating units, allowing for a real-world comparison of outcomes. Participants will be managed according to the standard post-operative supplementation protocol of their treating surgical unit; the research protocol does not assign interventions.
Study Cohorts
Eligible participants will be enrolled into one of two cohorts based on the standard care protocol of their surgical unit:
Prophylactic Iron Cohort: Patients whose standard care includes a daily prophylactic dose of 60 mg elemental iron (administered as Ferrodep®, 30 mg capsule every 12 hours) in addition to a daily standard multivitamin.
Standard Multivitamin Cohort: Patients whose standard care includes a daily standard multivitamin only (e.g., Centrum Silver®), which contains approximately 10 mg of iron, with no additional prophylactic iron.
Study Procedures and Assessments Consecutively enrolled patients scheduled for primary LSG will be assessed pre-operatively (baseline) and at 3 and 6 months post-operatively. Data collection will include standardized laboratory panels (hemoglobin, ferritin, iron studies, complete blood count indices), documentation of supplementation adherence, and patient-reported outcome measures. All primary and secondary outcome measures are pre-specified and listed in the designated module.
Statistical Considerations The primary outcome is the cumulative incidence of IDA at 6 months post-surgery, with IDA defined per protocol-specific laboratory criteria. Secondary outcomes include longitudinal changes in hematological parameters, adherence rates, and patient-reported fatigue. A sample size of 66 participants (33 per cohort) was calculated to provide 85% power to detect a significant difference in the primary outcome. Data will be analyzed using SPSS software with appropriate statistical tests for between-group comparisons, as detailed in the statistical analysis plan.
Adult patients with morbid obesity scheduled to undergo primary laparoscopic sleeve gastrectomy (LSG) at the participating bariatric surgery units.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients from the bariatric surgery unit whose standard postoperative care includes a prophylactic oral iron regimen. This consists of Ferrodep® (30 mg elemental iron per capsule), one capsule every 12 hours (total 60 mg/day), in addition to a daily standard multivitamin.
Drug: Elemental Iron · Dietary Supplement: Multivitamin with Minerals
Patients from the bariatric surgery unit whose standard postoperative care includes a daily standard multivitamin only (e.g., Centrum Silver®), which contains approximately 10 mg of iron. No additional prophylactic iron is routinely prescribed.
Dietary Supplement: Multivitamin with Minerals
Prophylactic oral iron supplement (Ferrodep®), prescribed as part of the standard post-operative care protocol at the participating unit. Each capsule contains 30 mg of elemental iron. The regimen is one capsule every 12 hours, for a total daily dose of 60 mg elemental iron, taken in addition to a daily multivitamin.
Drug pages: GeritolStudies of GeritolGeritol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MineralsStudies of MineralsMinerals pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
A standard daily multivitamin with minerals (Centrum Silver®), prescribed as part of the routine post-operative care. This formulation contains approximately 10 mg of elemental iron. For participants in this unit's protocol, no additional prophylactic iron is routinely prescribed.
Incidence of Iron Deficiency Anemia (IDA) at 6 Months
Proportion of participants diagnosed with IDA. Diagnosis requires: 1) Anemia (Hemoglobin \<13 g/dL in males or \<12 g/dL in females), AND 2) Iron Deficiency, defined by at least one of: serum ferritin \<30 ng/mL, TIBC \>450 µg/dL, or serum iron \<75 µg/dL (male)/\<60 µg/dL (female).
Time frame: 6 Months Post-Surgery
Change in Hemoglobin Concentration
Mean change in hemoglobin concentration (g/dL) from baseline to follow-up.
Time frame: Baseline, 3 Months, 6 Months
Change in Serum Ferritin Level
Mean change in serum ferritin concentration (ng/mL) from baseline to follow-up.
Time frame: Baseline, 3 Months, 6 Months
Change in Transferrin Saturation (TSAT)
Mean change in Transferrin Saturation percentage, calculated from serum iron and TIBC.
Time frame: Baseline, 3 Months, 6 Months
Incidence of Isolated Iron Deficiency without anemia
Proportion of participants with serum ferritin \<30 ng/mL and normal hemoglobin (≥12 g/dL female, ≥13 g/dL male).
Time frame: 3 Months, 6 Months
Rate of Oral Iron Intolerance
Proportion experiencing gastrointestinal effects leading to dose reduction, interruption, or discontinuation of iron.
Time frame: 6 Months Post-Surgery
Adherence to Oral Supplementation
Adherence expressed as the percentage of prescribed doses taken, calculated from pill count at follow-up clinic visits.
Time frame: 3 Months, 6 Months
Fatigue Severity Score]
Mean score on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale.The FACIT-Fatigue scale consists of 13 items, with total scores ranging from 0 to 52, where higher scores indicate less fatigue and better quality of life.
Time frame: Baseline, 3 Months, 6 Months
Need for Therapeutic Iron Supplementation
Proportion of participants who require initiation of new therapeutic iron during follow-up per clinician judgment.
Time frame: 6 Months Post-Surgery
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Nov 2026, 10 months after the start.
Of 49 non-industry observational studies under Anemia, Iron-Deficiency, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 40. This study's planned 10 months is below that.
Counting every sponsor, half of 54 studies reached it within 26 months; a quarter within 11 and three quarters within 35.
Primary completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → Nov 2026, on Oct 7, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.